GGrantIndex
← Leaderboards

Nigel T Maidment

University Of Maryland Baltimore

Google Scholar ↗PubMed ↗ORCID ↗
$12,633,034
Attributed
$23,360,844
Total exposure
17
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.2M · FY2006–25
$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$23,360,844 · 17

By mechanism

R01$13,632,926 · 6
P50$3,290,878 · 5
UH3$2,380,820 · 1
UG3$2,134,549 · 1
R21$1,921,671 · 4

Top collaborators

Others in their field

Top investigators on “Mediating”

Research focus

MediatingDopamineNeurochemistryBehaviorBrainNeuronsResponseMicrodialysisBehavioralAlzheimer&AposBaseLearningRewardsRattusCuesChronicOpioidEnkephalinsPharmaceutical PreparationsOpioid ReceptorExtracellularNucleus AccumbensAcuteIn Vivo

Grant awards (71)

Towards an iNPC-proSAAS therapy for Parkinson's disease$460,563
R21 · FY2025 · NS · contact PI
Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal, and the negative affective component of pain: a therapeutic screening tool.$793,584
UH3 · FY2024 · TR · contact PI
Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal, and the negative affective component of pain: a therapeutic screening tool.$793,584
UH3 · FY2023 · TR · contact PI
ProSAAS-mediated neuroprotective mechanisms in Alzheimer's and Parkinson's diseases: the role of secretory chaperones in neurodegeneration$633,662
R01 · FY2023 · AG
Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal, and the negative affective component of pain: a therapeutic screening tool.$793,652
UH3 · FY2022 · TR · contact PI
ProSAAS-mediated neuroprotective mechanisms in Alzheimer's and Parkinson's diseases: the role of secretory chaperones in neurodegeneration$633,662
R01 · FY2022 · AG
Changes across the lifespan in the use of heuristics to guide decision-making$711,784
R01 · FY2021 · AG
ProSAAS-mediated neuroprotective mechanisms in Alzheimer's and Parkinson's diseases: the role of secretory chaperones in neurodegeneration$633,662
R01 · FY2021 · AG
Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal, and the negative affective component of pain: a therapeutic screening tool.$531,057
UG3 · FY2021 · TR · contact PI
Changes across the lifespan in the use of heuristics to guide decision-making$758,584
R01 · FY2020 · AG
ProSAAS-mediated neuroprotective mechanisms in Alzheimer's and Parkinson's diseases: the role of secretory chaperones in neurodegeneration$633,662
R01 · FY2020 · AG
Cyto-ProSAAS Chaperone Action in Alzheimer's Disease and Frontotemporal Dementia$310,264
R01 · FY2020 · AG
Identifying motivational decision making deficits underlying the apathy domain in a rat model of Alzheimers disease$194,276
R21 · FY2020 · AG · contact PI
Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal and the negative affective component of pain: a therapeutic screening tool.$1,603,492
UG3 · FY2019 · TR · contact PI
Changes across the lifespan in the use of heuristics to guide decision-making$758,584
R01 · FY2019 · AG
ProSAAS-mediated neuroprotective mechanisms in Alzheimer's and Parkinson's diseases: the role of secretory chaperones in neurodegeneration$647,287
R01 · FY2019 · AG
Identifying motivational decision making deficits underlying the apathy domain in a rat model of Alzheimers disease$233,300
R21 · FY2019 · AG · contact PI
Multifunctional Microprobe for Multiple Neurotransmitter Sensing and Optogenetics$436,685
R01 · FY2018 · NS
Neurochemical bases for changes in decision-making across the lifespan$391,388
R01 · FY2018 · AG · contact PI
Multifunctional Microprobe for Multiple Neurotransmitter Sensing and Optogenetics$500,285
R01 · FY2017 · NS
Neurochemical bases for changes in decision-making across the lifespan$391,388
R01 · FY2017 · AG · contact PI
Multifunctional Microprobe for Multiple Neurotransmitter Sensing and Optogenetics$515,965
R01 · FY2016 · NS
Cafeteria diet-induced dysregulation of food seeking: neurochemical bases$400,015
R01 · FY2016 · DK · contact PI
Neurochemical bases for changes in decision-making across the lifespan$391,388
R01 · FY2016 · AG · contact PI
Circuits Mediationg Emotional Versus Motivational Components of Opioid Action$376,558
P50 · FY2016 · DA · contact PI
Multifunctional Microprobe for Multiple Neurotransmitter Sensing and Optogenetics$449,552
R01 · FY2015 · NS
Cafeteria diet-induced dysregulation of food seeking: neurochemical bases$414,408
R01 · FY2015 · DK · contact PI
Neurochemical bases for changes in decision-making across the lifespan$379,646
R01 · FY2015 · AG · contact PI
Circuits Mediationg Emotional Versus Motivational Components of Opioid Action$222,074
P50 · FY2015 · DA · contact PI
Insulin signaling, dopamine sensitization and cocaine cue-induced relapse$189,612
R21 · FY2015 · DA · contact PI
Multifunctional Microprobe for Multiple Neurotransmitter Sensing and Optogenetics$64,402
R01 · FY2015 · NS
Cafeteria diet-induced dysregulation of food seeking: neurochemical bases$14,393
R01 · FY2015 · DK · contact PI
Multifunctional Microprobe for Multiple Neurotransmitter Sensing and Optogenetics$518,852
R01 · FY2014 · NS
Neurochemical bases for changes in decision-making across the lifespan$391,388
R01 · FY2014 · AG · contact PI
Cafeteria diet-induced dysregulation of food seeking: neurochemical bases$328,168
R01 · FY2014 · DK · contact PI
Insulin signaling, dopamine sensitization and cocaine cue-induced relapse$231,000
R21 · FY2014 · DA · contact PI
Circuits Mediationg Emotional Versus Motivational Components of Opioid Action$225,128
P50 · FY2014 · DA · contact PI
Circuits Mediationg Emotional Versus Motivational Components of Opioid Action$216,122
P50 · FY2013 · DA · contact PI
Endogenous Opioid System Involvement In Cocaine-Seeking Behavior$289,154
R01 · FY2012 · DA · contact PI
Circuits Mediationg Emotional Versus Motivational Components of Opioid Action$225,128
P50 · FY2012 · DA · contact PI
Endogenous Opioid System Involvement In Cocaine-Seeking Behavior$289,154
R01 · FY2011 · DA · contact PI
Progression of Neurotransmitter Dysreg in Mouse and Cell Models of PD$373,273
P50 · FY2010 · NS · contact PI
Peptide Biomarkers of drug exposure: from brain microdialysate to plasma$304,920
R21 · FY2010 · DA · contact PI
Endogenous Opioid System Involvement In Cocaine-Seeking Behavior$298,097
R01 · FY2010 · DA · contact PI
Progression of Neurotransmitter Dysreg in Mouse and Cell Models of PD$345,013
P50 · FY2009 · NS · contact PI
Peptide Biomarkers of drug exposure: from brain microdialysate to plasma$308,000
R21 · FY2009 · DA · contact PI
Endogenous Opioid System Involvement In Cocaine-Seeking Behavior$301,108
R01 · FY2009 · DA · contact PI
Endogenous Opioid Systems Mediating Reward, Choice and Habit.$11
P50 · FY2009 · DA · contact PI
Progression of Neurotransmitter Dysreg in Mouse and Cell Models of PD$322,489
P50 · FY2008 · NS · contact PI
Endogenous Opioid System Involvement In Cocaine-Seeking Behavior$301,108
R01 · FY2008 · DA · contact PI
Endogenous Opioid Systems Mediating Reward, Choice and Habit.$15
P50 · FY2008 · DA · contact PI
Progression of Neurotransmitter Dysreg in Mouse and Cell Models of PD$325,214
P50 · FY2007 · NS · contact PI
Endogenous Opioid Systems Mediating Reward, Choice and Habit.$1
P50 · FY2007 · DA · contact PI
Progression of Neurotransmitter Dysreg in Mouse and Cell Models of PD$244,013
P50 · FY2006 · NS · contact PI
ROLE OF ENDOGENOUS OPIODS IN HEROIN ABUSE$220,769
R01 · FY2003 · DA
ROLE OF ENDOGENOUS OPIODS IN HEROIN ABUSE$214,338
R01 · FY2002 · DA
OPIOID RECEPTORS AND HEDONIC HOMEOSTASIS$0
P50 · FY2002 · DA
Chronic alterations in functional response to glutamate, GABA and dopamine$0
P50 · FY2002 · NS
Chronic alterations in functional response to glutamate, GABA and dopamine$0
P50 · FY2002 · NS
Chronic alterations in functional response to glutamate, GABA and dopamine$0
P50 · FY2002 · NS
CORE--ANALYTICAL NEUROCHEMISTRY$0
P50 · FY2002 · DA
ORPHANIN FQ OPIOID INTERACTIONS IN THE REGULATION OF BRAIN REWARD SYSTEMS$0
P50 · FY2002 · DA
ROLE OF ENDOGENOUS OPIODS IN HEROIN ABUSE$208,092
R01 · FY2001 · DA
Chronic alterations in functional response to glutamate, GABA and dopamine$32,217
P50 · FY2001 · NS
CORE--ANALYTICAL NEUROCHEMISTRY$0
P50 · FY2001 · DA
Chronic alterations in functional response to glutamate, GABA and dopamine$0
P50 · FY2001 · NS
ORPHANIN FQ OPIOID INTERACTIONS IN THE REGULATION OF BRAIN REWARD SYSTEMS$0
P50 · FY2001 · DA
ROLE OF ENDOGENOUS OPIODS IN HEROIN ABUSE$202,032
R01 · FY2000 · DA
Chronic alterations in functional response to glutamate, GABA and dopamine$145,042
P50 · FY2000 · NS
CORE--ANALYTICAL NEUROCHEMISTRY$119,290
P50 · FY2000 · DA
ORPHANIN FQ OPIOID INTERACTIONS IN THE REGULATION OF BRAIN REWARD SYSTEMS$119,290
P50 · FY2000 · DA